Key result
Fetal echocardiographic surveillance detected AVB II or III in 2.9% of pregnancies without a CHB history and 12.5% with a history, though fetal AV interval poorly predicted progression.
Why the study?
To investigate whether fetal AVB could be detected and treated before becoming complete and irreversible, and to establish the incidence of AVB I, II, and III.
Does weekly fetal echocardiographic surveillance allow for timely detection and treatment of atrioventricular block in anti-Ro52-positive pregnancies?
Cohort (n=212)
No
Does weekly fetal echocardiographic surveillance allow for timely detection and treatment of atrioventricular block in anti-Ro52-positive pregnancies?
Weekly fetal echocardiographic surveillance in anti-Ro52-positive pregnancies allows for early detection of AVB II or III, enabling timely betamethasone treatment which may restore conduction in AVB II and delay pacemaker need in AVB III.
No takes yet. Share an insight, caveat, or question.
Supports surveillance for early AVB II detection in anti-Ro52 pregnancies; leaves open betamethasone efficacy and need for RCTs.
Sonesson et al. (2019) conducted a cohort in Congenital heart block (n=212). Fetal echocardiographic surveillance was evaluated on Incidence of AVB I, II and III. Fetal echocardiographic surveillance detected AVB II or III in 2.9% of pregnancies without a CHB history and 12.5% with a history, though fetal AV interval poorly predicted progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: